广州医药 ›› 2018, Vol. 49 ›› Issue (5): 57-60.DOI: 10.3969/j.issn.1000-8535.2018.05.014

• 论著 • 上一篇    下一篇

米氮平联合文拉法辛对难治性抑郁症患者认知功能及生活质量影响的观察

郭彦杨, 赖志娜   

  1. 惠州市第二人民医院 (惠州 516001)
  • 收稿日期:2018-04-04 出版日期:2018-09-20 发布日期:2021-11-29

Observation of effects of mirtazapine and venlafaxine in treatment of the cognitive function and life quality in refractory depression patients

GUO Yanyang, LAI Zhina   

  1. Huizhou Second People's Hospital,Huizhou 516001,China
  • Received:2018-04-04 Online:2018-09-20 Published:2021-11-29

摘要: 目的 研究米氮平和文拉法辛二药连用治疗抑郁症的临床疗效和安全性,以及对患者认知功能及生活质量的影响。方法 选取125例抑郁症患者随机分为三组,A组42例给予文拉法辛,B组41例给予米氮平,C组42例给予米氮平及文拉法辛,疗程均为8周。采用HAMD-17、GQOLI-74集WMS-RC量表作为评价指标。结果 用药8周后总有效率比较,C组>B组>A组,同时,C组与其他两组比较有差异(P<0.05)。治疗前,三组患者WMS-RC各项评分比较无差异(P>0.05),治疗8周后,三组患者各项认知功能均有改善;其中,联合用药的改善效果最为显著。相较于治疗前,三组患者GQOLI-74评分均有不同程度上升,但C组患者上升幅度更大(P<0.05)。结论 联合应用来治疗难治性抑郁症疗效显著,且能帮助恢复患者的认知能力,研究过程中未发现较明显不良反应,故提倡临床推广。

关键词: 米氮平, 文拉法辛, 难治性抑郁症, 认知功能, 生活质量

Abstract: Objective To study on the clinical efficacy and safety of mirtazapine and venlafaxine in the treatment of refractory depression, as well as to improve cognitive function and quality of life in patients. Methods 125 patients were randomly assigned to three groups, including group A: 42 cases with venlafaxine, group B: 41 cases with mirtazapine, group C 42 cases with mirtazapine and venlafaxine, 8 weeks for a course. Results After the treatment, total effective rate: group C>group B>group A. There's no difference between WMS-RC among three groups. After treatment for 8 weeks, cognitive function of three groups was enhanced, and group C was the most significant. GQOLI-74 scores of the three groups were increased, but group C of patients increased even more sharply (P<0.05). Conclusion Mirtazapine and venlafaxine may effectively improve the quality of life and cognitive function of patients with depression. It's high safety and worthy of clinical promotion and application.

Key words: Venlafaxine, Mirtazapine, Refractory depression, Cognitive function, Quality of life